TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants legally competent to sign and give informed consent~* Males and females ages 18 years and older (inclusive)~* Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator~* Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.~* In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.~* Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.~Exclusion Criteria:~* Planned excessive exposure of treated area(s) to either natural or artificial sunlight or tanning bed.~* Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.~* Previous treatment with roflumilast cream or its active ingredient~* Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.~* Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.~* Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast Cream 0.3% (Type: EXPERIMENTAL): Roflumilast cream 0.3% topically applied QD for 12 weeks.
- Roflumilast Cream 0.15% (Type: EXPERIMENTAL): Roflumilast cream 0.15% topically applied QD for 12 weeks.
- Vehicle Cream (Type: PLACEBO_COMPARATOR): Vehicle cream matched to roflumilast cream (containing only excipients of active cream) applied QD for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Subjects with HIV-1 infection.~* Are willing and able to understand and provide written consent prior to participation in this study.~Exclusion criteria:~* Are pregnant or breastfeeding.~* Have an active AIDS condition, pancreatitis, poor kidney function, or clinically relevant hepatitis.~* Have certain medical conditions that may make participation unsafe.~* Take medication that may interact with the study medication.~* Have a history of allergy to any of the study drugs or any excipients therein.~* Other inclusion/exclusion criteria to be evaluated by the physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FPV/r200 (Type: ACTIVE_COMPARATOR): Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
- FPV/r100 (Type: EXPERIMENTAL): Fosamprenavir/ritonavir 1400/100mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic adult Fabry patients (≥18 yrs)~* Males: plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than lower limit of normal (LLN in plasma=3.2 nmol/hr/ml, LLN in leucocytes=32 nmol/hr/mg/protein)~* Females: historical genetic test results consistent with Fabry mutations~* Globotriaosylceramide (Gb3) concentration in urine \> 1.5 times upper normal limit~* Patients who have never received enzyme replacement therapy (ERT) in the past, or patients who have not received ERT in the past 6 months and have a negative anti alpha galactosidase antibody test~* eGFR ≥ 60 mL/min/1.73m2~* The patient signs informed consent~* Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically acceptable method of contraception, not including the rhythm method~Exclusion Criteria:~* Participation in any trial of an investigational drug within 30 days prior to study screening~* Chronic kidney disease stages 3-5 (CKD 3-5) (Appendix 7)~* History of dialysis or renal transplantation~* Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated or dose changed in the 4 weeks prior to screening~* Severe myocardial fibrosis by MRI (≥2 late-enhancement \[LE\] positive left ventricular segments) (Weidemann et al. 2009)~* History of clinical stroke~* Pregnant or nursing~* Presence of HIV and/or HBsAg and/or Hepatitis C infections~* Known allergies to ERT~* Known allergy to Gadolinium based contrast agents~* Presence of any medical, emotional, behavioral or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient's compliance with the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.2 mg/kg (Type: EXPERIMENTAL): PRX-102 0.2 mg/kg every 2 weeks
- 1 mg/kg (Type: EXPERIMENTAL): PRX-102 1 mg/kg every 2 weeks
- 2 mg/kg (Type: EXPERIMENTAL): PRX-102 2 mg/kg every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Localized prostate cancer: PSA (Prostate Specific Antigen) prior to radical prostatectomy \< 10 ng/ml, histopathologic analysis of the prostate showing a prostate cancer with Gleason score ≤ 7, negative margin, absence of effraction of the prostatic capsule, pT1 or pT2 N0 or NX.~* PSA=0 ng/ml 6 months after radical prostatectomy.~* Normal erectile function prior to radical prostatectomy.~* Penile arterial insufficiency and or venous leakage (doppler) at the time of inclusion: PSV \<25 cm/sec, PSV \>25 cm/sec, EDV\>5cm/sec, RI\<0,75.~Exclusion Criteria:~* Non localized prostate cancer.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- injection of bone marrow cells (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years, with chronic genotype 1 HCV infection~* HCV RNA equal to or greater than 10,000 IU/mL at screening~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 8 Weeks (TN) (Type: EXPERIMENTAL): Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
- LDV/SOF+RBV 8 Weeks (TN) (Type: EXPERIMENTAL): Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
- LDV/SOF 12 Weeks (TN) (Type: EXPERIMENTAL): Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
- LDV/SOF 12 Weeks (TE) (Type: EXPERIMENTAL): Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor \[PI\]+pegylated interferon \[PEG\]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
- LDV/SOF+RBV 12 Weeks (TE) (Type: EXPERIMENTAL): Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with CD22-positive ALL with either refractory disease (i.e. disease progression or no response while receiving their most recent prior anti-cancer therapy), or relapsed disease (i.e. response to their most recent prior anti-cancer therapy with subsequent relapse). Subjects enrolled in the Phase 2 portion of the study must be due to receive salvage 2 or later therapy.~* Subjects with Philadelphia chromosome-positive (Ph+) ALL must have failed standard treatment with at least one tyrosine kinase inhibitor.~* Adequate renal and hepatic function, and negative pregnancy test for women of childbearing potential.~Exclusion Criteria:~* Subjects with isolated extramedullary relapse or active central nervous system (CNS) leukemia.~* Prior allogeneic hematopoietic stem cell transplant (HSCT) or other anti-CD22 immunotherapy within 4 months, or active graft versus host disease (GvHD) at study entry.~* Evidence or history of veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inotuzumab Ozogamicin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants from whom embryos have been cryopreserved in Base Trial P05787 (NCT00696800), of which at least one embryo is thawed for use in a subsequent FTET cycle;~* Able and willing to give informed consent.~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- 150 µg Corifollitropin Alfa (Type: None): Participants from the base study P05787 (NCT00696800), received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (Org 36286) on menstrual cycle Day 2/3 (Day 1); 7 daily SC injections from Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG). Daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles \>= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started, for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
- 200 IU RecFSH (Type: None): Participants from the base study P05787 (NCT00696800), received a single SC injection of placebo Corifollitropin Alfa on menstrual cycle day 2/3 (Day 1); 7 daily SC injections with 200 IU recFSH from Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Multiple daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles \>= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Entry criteria include the following:~1. Clinical diagnosis of VOD, made by Baltimore Criteria, Modified Seattle Criteria, or biopsy proven:~   1.1 Baltimore Criteria- Bilirubin ≥2 mg/dL and at least 2 of the following clinical findings:~  * Ascites (radiographic or physical exam)~  * Weight gain of ≥5% compared to the day of conditioning-- if this value is not available, the weight on the date of admission to the SCT unit may be used)~  * Hepatomegaly; increased over baseline.~   1.2 Modified Seattle Criteria: At least two of the following~  * Bilirubin ≥2 mg/dL~  * Ascites (radiographic or physical exam) and/or weight gain ≥5% above baseline weight (defined as weight on the first day of conditioning- if this value is not available, the weight on the date of admission to the SCT unit may be used)~  * hepatomegaly increased over baseline~   1.3 Patients that do not meet the Baltimore Criteria or Modified Seattle Criteria and have biopsy proven VOD are eligible.~2. Patient must also provide written informed consent.~Exclusion Criteria:~* Use of any medication which increases the risk of hemorrhage is disallowed. Use of heparin or other anticoagulants is disallowed within 12 hours unless being used for routine central venous line management, fibrinolytic instillation for central venous line occlusion, intermittent dialysis or ultrafiltration of CVVH.~* Clinically significant uncontrolled acute bleeding, defined as hemorrhage requiring \> 15 cc/kg of packed red blood cells (e.g., a pediatric patient weighing 20 kg and requiring \> 300cc of packed red blood cells/24 hours, or an adult patient weighing 70 kg and requiring \>3 units of packed red blood cells/24 hours) to replace blood loss, OR bleeding from a site which in the Investigator's opinion constitutes a potential life-threatening source (e.g. pulmonary hemorrhage or CNS bleeding), irrespective of amount of blood loss, at any point from the date of SCT through the date of severe VOD diagnosis.~* Hemodynamic instability as defined by a requirement for multiple pressors, or inability to maintain mean arterial pressure (for children: to maintain mean arterial pressure within 1 standard deviation of age-adjusted levels) with single pressor support.~* Woman who are pregnant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Defibrotide (Type: EXPERIMENTAL): Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neuroimaging Attentional Impairment During Abstinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. smoked an average of 10 cigarettes per day for two years~2. a brand that delivers (by Federal Trade Commission rated yields) at least 0.5 mg nicotine~3. have an expired air carbon monoxide reading of at least 10 ppm.~4. be in general good health~5. Participants with controlled medical conditions (e.g., hypertension) will be considered if treatment is not thought to interfere with fMRI measures or potentially ameliorate smoking withdrawal symptoms~Exclusion Criteria:~1. Individuals with a major medical condition that would make participation unsafe (e.g., have pacemaker or other metallic implant),~2. uncomfortable (e.g., chronic pain),~3. confound results (e.g., psychiatric condition)~4. suffering from claustrophobia; abnormally afraid of closed-in places will be excluded from participation,~5. Current alcohol or drug abuse,~6. smokeless tobacco use, or use of nicotine replacement therapy or other smoking cessation treatment will also be a basis for exclusion and evaluated via a urine test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Smokers not interested in quitting smoking (Type: EXPERIMENTAL): Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Parallel Arm Trial of AD109 and AD504 In Patients With OSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 to 65 years of age for men and 18-75 for women, inclusive, at the Screening Visit.~* Mean AHI 10 to 45 events/h, inclusive~* PGI-S: \>1~Exclusion Criteria:~* Current clinically significant sleep disorder other than OSA~* Clinically significant craniofacial malformation.~* Clinically significant cardiac disease (e.g. rhythm disturbances, coronary artery disease or heart failure or hypertension requiring more than 2 medications for control).~* Participants with a history of using devices for OSA treatment, including CPAP, oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 2 weeks prior to first PSG and are not used during participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AD109 Dose 1 (Type: EXPERIMENTAL): None
- AD109 Dose 2 (Type: EXPERIMENTAL): None
- AD504 Dose 1 (Type: EXPERIMENTAL): None
- AD504 Dose 2 (Type: EXPERIMENTAL): None
- Atomoxetine 1 (Type: ACTIVE_COMPARATOR): None
- Atomoxetine 2 (Type: ACTIVE_COMPARATOR): None
- Placebo 1 (Type: PLACEBO_COMPARATOR): None
- Placebo 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Measurable and symptomatic Multicentric Castleman's Disease~* Adequate organ function as assessed by laboratory values evaluated by the investigator to determine eligibility prior to treatment~* Eastern Cooperative Oncology Group performance status of 0, 1, or 2~* Corticosteroids dose that does not exceed 1 mg/kg/day of prednisone, and has remained stable or decreased over the 4 weeks before treatment~Exclusion Criteria:~* Human Immunodeficiency Virus or Human Herpes Virus-8 positive~* Skin lesions as sole measurable manifestation of Multicentric Castleman's Disease~* Previous history of lymphoma~* Malignancies, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or cancer other than lymphoma, from which the patient has been disease-free for 3 or more years~* Concurrent medical condition or disease that may interfere with study participation~* Prior exposure to Interleukin-6 or Interleukin-6 receptor targeted therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siltuximab+best supportive care (BSC) (Type: EXPERIMENTAL): Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
- Placebo+BSC (Type: PLACEBO_COMPARATOR): Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC. Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete